2626-52-0

Usage

Uses

Used in Pharmaceutical Industry:
3-(DIETHYLAMINO)PROPYL ISOTHIOCYANATE is used as a reagent for the synthesis of GCS-g-DEAP, which is glycol chitosan (GCS) grafted with DEAP groups. 3-(DIETHYLAMINO)PROPYL ISOTHIOCYANATE has potential applications in drug delivery systems, as it can enhance the solubility, stability, and bioavailability of drugs, leading to improved therapeutic outcomes.
Used in Chemical Synthesis:
3-(DIETHYLAMINO)PROPYL ISOTHIOCYANATE is also used as a reagent in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its isothiocyanate functional group allows for a wide range of chemical reactions, making it a versatile building block in organic synthesis.

InChI:InChI=1/C8H16N2S/c1-3-10(4-2)7-5-6-9-8-11/h3-7H2,1-2H3

Upstream product

• 19022-72-1 N-(2-diethylaminopropyl)-dithiocarbamic acid 
• 75-15-0 carbon disulfide 
• 104-78-9 diethylaminopropylamine 

Downstream Products

• 86503-21-1 5-Benzyl-3-(3-diethylamino-propyl)-2-thioxo-imidazolidin-4-one 
• 106859-54-5 N-[3-(Diethylamino)propyl]-3-[3-(trifluoromethyl) phenoxy]-1-azetidinecarbothioamide, oxalate 
• 1290181-77-9 3-(5-(3-(diethylamino)propylamino)-1,3,4-oxadiazol-2-yl)-6-(2-fluoro-4-methoxyphenyl)-4-methyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 
• 309246-83-1 GVNDNEEGFFSAR 
• 109341-26-6 cyclohexyl-(3-diethylamino-propyl)-carbodiimide 
• 97236-87-8 N-<3-Diethylamino-propyl>-thiobenzamid 
• 106476-26-0 N-cyclohexyl-N'-(3-diethylamino-propyl)-thiourea 

Relevant academic research and scientific papers

Synthesis of new alkylaminoalkyl thiosemicarbazones of 3-acetylindole and their effect on DNA synthesis and cell proliferation

The preparation of a number of thiobemicarbazones of 3-acetylindole is described. These compounds were evaluated in vitro for their effect on proliferation and cell-division delays in cultured human peripheral blood lymphocytes, and their effect on DNA synthesit in T-cell leukemia Molt-4 cells.

Regioselective covalent modification of hemoglobin in search of antisickling agents

Although the molecular defect in sickle hemoglobin that produces sickle cell disease has been known for decades, there is still no effective drug treatment that acts on hemoglobin itself. In this work, a series of diversely substituted isothiocyanates (R-NCS) were examined for their regioselective reaction with hemoglobin in an attempt to alter the solubility properties of sickle hemoglobin. Electrospray mass spectrometry, molecular modeling, X-ray crystallography, and conventional protein chemistry were used to study this regioselectivity and the resulting increase in solubility of the modified hemoglobin. Depending on the attached R-group, the isothiocyanates were found to react either with the Cysβ93 or the N-terminal amine of the α-chain. One of the most effective compounds in the series, 2-(N,N-dimethylamino)ethyl isothiocyanate, selectively reacts with the thiol of Cysβ93 which, in conjunction with the cationic group, was seen to perturb the local hemoglobin structure. This modified HbS shows an approximately 30% increase in solubility for the fully deoxygenated state, along with a significant increase in oxygen affinity. This compound and a related analogue appear to readily traverse the erythrocyte membrane. A discussion of the relation of these structural changes to inhibition of gelation is presented. The dual activities of increasing HbS oxygen affinity and directly inhibiting deoxy HbS polymerization, in conjunction with facile membrane traversal, suggest that these cationic isothiocyanates show substantial promise as lead compounds for development of therapeutic agents for sickle cell disease.